Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Network analysis identifies Rv0324 and Rv0880 as regulators of bedaquiline tolerance in Mycobacterium tuberculosis


The resilience of Mycobacterium tuberculosis (MTB) emerges from its ability to effectively counteract immunological, environmental and antitubercular challenges. Here, we demonstrate that MTB can tolerate drug treatment by adopting a tolerant state that can be deciphered through systems analysis of its transcriptional responses. Specifically, we demonstrate how treatment with the antitubercular drug bedaquiline activates a regulatory network that coordinates multiple resistance mechanisms to push MTB into a tolerant state. Disruption of this network, by knocking out its predicted transcription factors, Rv0324 and Rv0880, significantly increased bedaquiline killing and enabled the discovery of a second drug, pretomanid, that potentiated killing by bedaquiline. We demonstrate that the synergistic effect of this combination emerges, in part, through disruption of the tolerance network. We discuss how this network strategy also predicts drug combinations with antagonistic interactions, potentially accelerating the discovery of new effective combination drug regimens for tuberculosis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Bedaquiline response networks regulated by Rv0324 and Rv0880.
Figure 2: Killing of ΔRv0324 and ΔRv0880 MTB strains by bedaquiline.
Figure 3: Influence of Rv0880 overexpression on EOB estimation of bedaquiline and pretomanid drug combination.


  1. 1

    Phillips, L. Infectious disease: TB's revenge. Nature 493, 14–16 (2013).

    Article  Google Scholar 

  2. 2

    Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397–2405 (2009).

    Article  Google Scholar 

  3. 3

    Koul, A. et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nature Commun. 5, 3369 (2014).

    Article  Google Scholar 

  4. 4

    Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chem. Biol. 3, 323–324 (2007).

    Article  Google Scholar 

  5. 5

    Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273–25280 (2008).

    Article  Google Scholar 

  6. 6

    Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223–227 (2005).

    Article  Google Scholar 

  7. 7

    Peterson, E. J. et al. A high-resolution network model for global gene regulation in Mycobacterium tuberculosis. Nucleic Acids Res. 42, 11291–11303 (2015).

    Article  Google Scholar 

  8. 8

    Turkarslan, S. P. E. et al. A comprehensive map of genome-wide gene regulation in Mycobacterium tuberculosis. Sci. Data 2, 150010 (2015).

    Article  Google Scholar 

  9. 9

    Ma, S. et al. Integrated modeling of gene regulatory and metabolic networks in Mycobacterium tuberculosis. PLoS Comput. Biol. 11, e1004543 (2015).

    Article  Google Scholar 

  10. 10

    Chandrasekaran, S. & Price, N. D. Probabilistic integrative modeling of genome-scale metabolic and regulatory networks in Escherichia coli and Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 107, 17845–17850 (2010).

    Article  Google Scholar 

  11. 11

    Reiss, D. J., Baliga, N. S. & Bonneau, R. Integrated biclustering of heterogeneous genome-wide datasets for the inference of global regulatory networks. BMC Bioinformatics 7, 280 (2006).

    Article  Google Scholar 

  12. 12

    Lew, J. M., Kapopoulou, A., Jones, L. M. & Cole, S. T. TubercuList—10 years after. Tuberculosis (Edinb) 91, 1–7 (2011).

    Article  Google Scholar 

  13. 13

    Forrellad, M. A. et al. Virulence factors of the Mycobacterium tuberculosis complex. Virulence 4, 3–66 (2013).

    Article  Google Scholar 

  14. 14

    Senaratne, R. H. et al. Mycobacterium tuberculosis strains disrupted in mce3 and mce4 operons are attenuated in mice. J. Med. Microbiol. 57, 164–170 (2008).

    Article  Google Scholar 

  15. 15

    Shlomi, T., Cabili, M. N., Herrgard, M. J., Palsson, B. O. & Ruppin, E. Network-based prediction of human tissue-specific metabolism. Nature Biotechnol. 26, 1003–1010 (2008).

    Article  Google Scholar 

  16. 16

    Zur, H., Ruppin, E. & Shlomi, T. iMAT: an integrative metabolic analysis tool. Bioinformatics 26, 3140–3142 (2010).

    Article  Google Scholar 

  17. 17

    Rustad, T. R. et al. Mapping and manipulating the Mycobacterium tuberculosis transcriptome using a transcription factor overexpression-derived regulatory network. Genome Biol. 15, 502 (2014).

    Article  Google Scholar 

  18. 18

    Tufariello, J. M. et al. Enhanced specialized transduction using recombineering in Mycobacterium tuberculosis. mBio 5, e01179–e01114 (2014).

    Article  Google Scholar 

  19. 19

    Ioerger, T. R. et al. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS ONE 8, e75245 (2013).

    Article  Google Scholar 

  20. 20

    Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962–966 (2000).

    Article  Google Scholar 

  21. 21

    Minch, K. J. et al. The DNA-binding network of Mycobacterium tuberculosis. Nature Commun. 6, 5829 (2015).

    Article  Google Scholar 

  22. 22

    Bansal, M. et al. A community computational challenge to predict the activity of pairs of compounds. Nature Biotechnol. 32, 1213–1222 (2014).

    Article  Google Scholar 

  23. 23

    Hards, K. et al. Bactericidal mode of action of bedaquiline. J. Antimicrob. Chemother. 70, 2028–2037 (2015).

    Google Scholar 

  24. 24

    Berney, M., Hartman, T. E. & Jacobs, W. R. Jr. A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline. mBio 5, e01275–e01214 (2014).

    Article  Google Scholar 

  25. 25

    Lu, P. et al. The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress. Sci. Rep. 5, 10333 (2015).

    Article  Google Scholar 

  26. 26

    Pethe, K. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nature Med. 19, 1157–1160 (2013).

    Article  Google Scholar 

  27. 27

    Boshoff, H. I. et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279, 40174–40184 (2004).

    Article  Google Scholar 

  28. 28

    Telenti, A. et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341, 647–650 (1993).

    Article  Google Scholar 

  29. 29

    Keren, I., Shah, D., Spoering, A., Kaldalu, N. & Lewis, K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J. Bacteriol. 186, 8172–8180 (2004).

    Article  Google Scholar 

  30. 30

    Keren, I., Kaldalu, N., Spoering, A., Wang, Y. & Lewis, K. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230, 13–18 (2004).

    Article  Google Scholar 

  31. 31

    Smith, P. A. & Romesberg, F. E. Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. Nature Chem. Biol. 3, 549–556 (2007).

    Article  Google Scholar 

  32. 32

    Pandey, D. P. & Gerdes, K. Toxin–antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes. Nucleic Acids Res. 33, 966–976 (2005).

    Article  Google Scholar 

  33. 33

    Sala, A., Bordes, P. & Genevaux, P. Multiple toxin–antitoxin systems in Mycobacterium tuberculosis. Toxins (Basel) 6, 1002–1020 (2014).

    Article  Google Scholar 

  34. 34

    Dhillon, J., Andries, K., Phillips, P. P. & Mitchison, D. A. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis 90, 301–305 (2010).

    Article  Google Scholar 

  35. 35

    Diacon, A. H. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380, 986–993 (2012).

    Article  Google Scholar 

  36. 36

    Tasneen, R. et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55, 5485–5492 (2011).

    Article  Google Scholar 

  37. 37

    Our Pipeline: Regimens TB Alliance, (2016);

  38. 38

    A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects with Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis (NC-005) (National Institutes of Health, 2015);

  39. 39

    Diacon, A. H. et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am. J. Respir. Crit. Care Med. 191, 943–953 (2015).

    Article  Google Scholar 

  40. 40

    A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline plus PA-824 plus Linezolid in Subjects with Drug Resistant Pulmonary Tuberculosis (National Institutes of Health, 2015);

  41. 41

    R Development Core Team. A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2013).

  42. 42

    Rogers, D. J. & Tanimoto, T. T. A computer program for classifying plants. Science 132, 1115–1118 (1960).

    Article  Google Scholar 

  43. 43

    Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).

    Article  Google Scholar 

  44. 44

    Rustad, T. R., Harrell, M. I., Liao, R. & Sherman, D. R. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS ONE 3, e1502 (2008).

    Article  Google Scholar 

  45. 45

    Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).

    Article  Google Scholar 

  46. 46

    Ma, S. et al. Integrated modeling of gene regulatory and metabolic networks in Mycobacterium tuberculosis. PLoS Comput. Biol. 11, 1004543 (2015).

    Article  Google Scholar 

  47. 47

    Becker, S. A. et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox. Nature Protoc. 2, 727–738 (2007).

    Article  Google Scholar 

  48. 48

    Schellenberger, J. et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. Nature Protoc. 6, 1290–1307 (2011).

    Article  Google Scholar 

  49. 49

    Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl Acad. Sci. USA 100, 7977–7982 (2003).

    Article  Google Scholar 

Download references


The authors thank members of the Baliga and Sherman laboratories for discussions, T. Rustad, J. Winkler and S. Hobbs for generating knockout and overexpressing strains, and Z. Simon, M. Sarvothama and R. Liao for technical help. Funding was provided by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (U19 AI10676, U19 AI111276 and ISBpilot-10135) and the National Institute of General Medical Sciences of the National Institutes of Health (P50GM076547).

Author information




E.J.R.P. led the design and drafted the manuscript. E.J.R.P. and S.M. generated results and analysed data. S.M. helped design the study and helped draft online methods. D.R.S. helped designed the study, discussed results and commented on the manuscript. N.S.B. conceived of the study, discussed the results and drafted the manuscript.

Corresponding author

Correspondence to Nitin S. Baliga.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

Supplementary Figures 1-8 and Supplementary Tables 4 and 5. (PDF 2195 kb)

Supplementary Tables

Supplementary Tables 1–3 (XLSX 58 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peterson, E., Ma, S., Sherman, D. et al. Network analysis identifies Rv0324 and Rv0880 as regulators of bedaquiline tolerance in Mycobacterium tuberculosis. Nat Microbiol 1, 16078 (2016).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing